Comparing Pegaptanib and Triamcinolone Efficacy in the Rat Choroidal Neovascularization Model

Abstract

To evaluate the prophylactic effect of intravitreal pegaptanib sodium on choroidal neovascularization membrane (CNVM) development and compare its performance with that of triamcinolone acetonide. Methods: In drug-treated and control groups, CNVMs were induced by laser trauma. Immediately after undergoing the laser procedure, animals received intravitreal injections of pegaptanib sodium, 8 or 17 µg; triamcinolone acetonide, 200 µg; or a vehicle solution. After 21 days, fluorescein angiography was performed. The CNVM mean diameters and radial thicknesses were measured histologically. Results: Mean CNVM diameters were 10% to 13% smaller in pegaptanib-treated eyes and 43% smaller in triamcinolone-treated eyes compared with laser-only control eyes. Late-stage fluorescein angiography leakage scores, on a scale of 0 to 3, suggested a statistical difference between triamcinolone-(0.6) and pegaptanib 8 µg-treated (1.5) groups compared with the laser-only control group (2.0). The CNVM mean thicknesses were greater in the pegaptanib 8 µg-(79 µm) and pegaptanib 17 µg-treated (71 µm) groups and significantly smaller in the triamcinolonetreated group (26 µm) compared with the laser-only control group (67 µm). Conclusion: In this animal model of choroidal neovascularization, intravitreal pegaptanib exhibited marginal or no effect on CNVM development; whereas intravitreal triamcinolone evoked robust inhibition of CNVMs. Clinical Relevance: Pegaptanib treatment may be insufficient to prevent CNVM formation.

Dexamethasone Intravitreal Implant as Adjunctive Therapy to Ranibizumab in Neovascular Age-Related Macular Degeneration: A Multicenter Randomized Controlled Trial

“…High-dose corticosteroid pulse dosing has been shown to cause apoptosis of cells involved in an inflammatory response, including peripheral T cells and eosinophils [22,23,24]. In animal models, intravitreal corticosteroid injections have been shown to inhibit both VEGF production [25] and CNV membrane development [26]. …”

In Vivo Imaging of a New Indocyanine Green Micelle Formulation in an Animal Model of Laser-Induced Choroidal Neovascularization

“…[24][25][26][27][28][29] For example, imaging of real-time retinal cell apoptosis 25 and laser-induced CNV has been reported. [30][31][32][33][34] The aim of the current study was to develop a new formulation of ICG with better chemical stability and modified Copyright 2014 The Association for Research in Vision and Ophthalmology, Inc. www.iovs.org j ISSN: 1552-5783 fluorescence characteristics, and to test this molecule in vitro and in an animal model with in vivo and ex vivo correlations. The potentially better and longer visualization of this modified dye may be helpful for an improved detection and monitoring of pathological alterations in various eye diseases.…”

Respuestas tisulares y vasculares en retinopatía hipertensiva con anticuerpos monoclonales como terapia antiangiogénica

“…Las variables de estudio fueron fuga vascular asociada con los procesos de neovascularización, mejoría en AV y reducción de edema macular. Se revisaron para esta categoría varios estudios preclínicos de modelos de retinopatía hipertensiva y diabética con angiogénesis y cambios maculares en progreso, que muestran un 96,6 % de mejoría en estas variables ( Criswell, 2008;Hossein y Chader, 2007;Hu, Gale y Shields, 2012).…”

“…En este sentido, en los estudios de Bakri, Reid y Snyder (2007) y Mitchell et al (2010) se demuestra mejoría del 46,96 % de los participantes. De igual manera, en el trabajo de Criswell (2008) se pudo observar que por medio de la inyección de ranibizumab y triamcinolona intravítrea combinados, hubo una mejoría del 100 % en fuga vascular y disminución de la hiperfluorescencia.…”